Modality
Multispecific
MOA
TROP-2 ADC
Target
SHP2
Pathway
Hedgehog
Endometrial CaFSGSLGS
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
~May 2017
→ ~Aug 2018
Phase 2
Nov 2018
→ Apr 2030
Phase 2Current
NCT04647345
900 pts·FSGS
2018-11→2030-04·Terminated
900 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-014.0y awayPh2 Data· FSGS
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Termina…
Catalysts
Ph2 Data
2030-04-01 · 4.0y away
FSGS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04647345 | Phase 2 | FSGS | Terminated | 900 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 |